// App-Quantinova.ai

PATH-23 : GENOMIC LANDSCAPE OF IDH-MUTANT PRIMARY GLIOBLASTOMAS SHOWS DISTINCT CLINICAL AND MOLECULAR FEATURES AND THAT CDKN2A SHOULD BE SUPPLEMENTED WITH MGMTp AND G-CIMP FOR PRECISE PROGNOSTICATION

Researchers

Presenter

  • Queenie Hoi-Wing Wong

Principal Investigators

  • Aden Ka-Yin Chan

  • Wai Sang Poon

  • Danny Tat-Ming Chan

  • Hong Chen

  • Zhen-yu Zhang

  • Houtan Noushmehr

  • Chris Jones

  • Yura Grabovska

  • Alan Mackay

  • Chit Chow

  • Johnny Sheung Him Kwan

  • Nellie Yuk-Fei Chung

  • Queenie Junqi Huang

  • Manix Fung-Man Poon

  • Zhi-feng Shi

  • Kay Ka-Wai Li

  • Ho-Keung Ng

Medical Centers

  • The Chinese University of Hong Kong, Hong Kong, Hong Kong

  • Zhongshan Hospital, Fudan University, Shanghai, China (People's Republic)

  • the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic)

  • Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI, USA

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Zhongshan Hospital, Fudan University, Shanghai, China (People's Republic)

Locations

  • Hong Kong

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Glioblastoma

  • PDGFRA rearrangement

  • ATRX syndrome

Biomarkers

  • Alpha thalassemia mental retardation X-linked protein

  • MutS Homolog 6

  • Phosphatase and tensin homolog

  • Platelet Derived Growth Factor Receptor Alpha

  • cMYC

  • Cyclin D2

  • Cyclin Dependent Kinase Inhibitor 2A

  • Cyclin-dependent kinase 4

  • Retinoblastoma protein

  • Epidermal growth factor receptor

  • Tumor protein p53

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved